Malignancy-related tumor-induced osteomalacia is a rare but important entity. We report the first case of oncogenic renal phosphate wasting in the setting of a pancreaticobiliary malignancy. Our patient presented with refractory hypophosphatemia. Workup revealed high fibroblast growth factor 23 levels as well as a new pancreaticobiliary mass. All other causes of hypophosphatemia were ruled out. With tumor-induced osteomalacia, an accurate diagnosis and location of the offending tumor is essential for appropriate management and treatment.
Introduction
Oncogenic renal phosphate wasting secondary to fibroblast growth factor 23 (FGF23) secretion is a rare paraneoplastic syndrome, causing tumor-induced osteomalacia (TIO), also referred to as oncogenic osteomalacia. 1 A majority of the cases reported are caused by benign mesenchymal tumors of soft tissue or bone, but there are several cases in the literature of various malignant neoplasms secreting FGF23. Malignant neoplasm-induced TIO, however, is quite rare, making up less than 5% of cases of oncogenic osteomalacia. 2 Cases involved include malignant neoplasms such as small cell lung cancer, squamous cell cancer, colon cancer, prostate cancer, ovarian cancer, lymphoma, osteosarcoma, and multiple myeloma. [3] [4] [5] [6] [7] [8] [9] [10] [11] We present the first case of an FGF23-secreting pancreaticobiliary tumor causing oncogenic renal phosphate wasting.
Case report
We present the case of a 71-year-old female with no significant medical history who was admitted due to progressively worsening dyspnea on exertion, persistent abdominal pain and distention, and lower extremity edema which worsened over the course of 6 weeks. Review of systems was pertinent for a 50-pound unintentional weight loss over the past 2 months, despite a normal appetite. She denied any history of diarrhea. Her only medication was tramadol which was prescribed recently for abdominal pain. She denied any diuretic or antacid use. There was no significant history of alcohol, drug, or tobacco use. Family history was negative for any type of cancer or autoimmune disease.
Upon presentation, her initial vital signs included an oral temperature of 36.3°C, a heart rate of 100 bpm, a blood pressure of 154/81 mmHg, a respiratory rate of 19 breaths per minute, and an oxygen saturation of 97% on room air. Physical examination revealed an alert and oriented woman in no apparent distress. She had a flat affect. HEENT examination was negative for scleral icterus. Pulmonary examination revealed decreased breath sounds bilaterally. Cardiovascular examination Journal of Onco-Nephrology 2 (1) was unremarkable. Her abdomen was non-tender, but distended, dull on percussion, and positive for shifting dullness. There was 2+ pitting edema bilaterally in the lower extremities. Skin examination was negative for any ecchymosis, petechiae, rashes, or jaundice.
The patient's laboratory findings were significant for a calcium of 11.6 mg/dL (reference range: 8.4-10.5 mg/dL), an albumin of 2. Serum pro-brain natriuretic peptide was elevated to 614 pg/ mL (reference range: 0-300 pg/mL). Coagulation studies revealed a normal activated partial thromboplastin time of 31.7 s (reference range: 27.5-37.4 s), a slightly elevated prothrombin time of 14 s (reference range: 9.8-13.1 s), and an international normalized ratio (INR) of 1.28 (reference range: 0.88-1.17). Her complete blood count was normal. Urinalysis was negative for glucose or protein. Chest X-ray was notable for cardiomegaly. An abdominal and pelvis computed tomography (CT) with contrast was significant for marked heterogeneous attenuation concerning for multiple liver masses. In addition, there was evidence of liver cirrhosis with enlargement of the spleen and large volume ascites suggestive of portal hypertension.
Additional testing revealed negative hepatitis A, B, and C serologies. Smooth muscle antibody measurement was inconclusive at a dilution of 1:20 (reference range < 1:20). Anti-liver/kidney microsomal antibody, ANA, alpha-1-antitrypsin, and ceruloplasmin were all within normal limits. Iron studies revealed an iron level of 45 µg/dL (reference range: 30-160 µg/dL), ferritin level of 331 ng/mL (reference range: 15-150 ng/mL), a total iron-binding capacity of 136 µg/dL (reference range: 220-430 µg/dL), and a percent saturation of 33% (reference range: 14%-50%). Tumor markers were also evaluated. Alpha-fetoprotein was 10 ng/ mL (reference range: ≤8.3 ng/mL), Ca 19-9 was 52.2 U/mL (reference range: ≤41.3), and carcinoembryonic antigen (CEA) was 2 ng/mL (reference range: 0-3.8 ng/mL).
Further workup revealed an ionized Ca of 1.53 mmol/L (reference range: 1.05-1.34 mmol/L), intact parathyroid hormone (PTH) of 6 pg/mL (reference range: 15-65 pg/ mL), 25-hydroxyvitamin D level of 18.9 ng/mL (reference range: 30-100 ng/mL), 1-25-dihydroxyvitamin D level of 28.6 pg/mL (reference range: 19.9-79.3 pg/mL), PTH related peptide (PTHrP) level of 1.8 pmol/L (reference range: <2), kappa/lambda ratio of 1.98, and serum protein electrophoresis revealed no monoclonal band. Due to the lack of evidence of gastrointestinal phosphate wasting in the presence of persistent and refractory hypophosphatemia, it was suspected that she may have renal phosphate wasting. Random urine phosphorous was 134.4 mg/ dL, random urine creatinine was 117 mg/dL, fractional excretion of phosphorous was 48%, and FGF23 levels were 1310 RU/mL (reference range: ≤180 RU/mL). At this point, a diagnosis of TIO was strongly suspected.
An ultrasound-guided fine-needle aspiration and two core biopsies of the 2-cm liver mass revealed metastatic pancreaticobiliary adenocarcinoma. The patient subsequently developed jaundice, hepatic encephalopathy, and rapidly re-accumulating ascites, as well as persistent hypophosphatemia despite aggressive repletion. She was discharged home with hospice care.
Discussion
TIO is characterized by hypersecretion of FGF23. FGF23 is a phosphatonin made by osteocytes and plays a major role in the bone-kidney axis by regulating phosphate, 1,25-dihydroxyvitamin D (1,25(OH) 2 D), and bone mineralization. 12 In response to high serum phosphorous and vitamin 1,25(OH) 2 D levels, FGF23 is secreted. It then binds to the FGF receptor:Klotho complex in renal tubular epithelial cells, decreasing proximal tubule expression of sodium-phosphate co-transporter. This results in decreased phosphorous reabsorption, phosphaturia, and corresponding hypophosphatemia. 12 In addition, FGF23 inhibits 1α-hydroxylase activity in the proximal tubule by down regulation of CP27B1, thus decreasing 1,25(OH) 2 D levels. This, in turn, decreases phosphate absorption in the gut, which potentiates the hypophosphatemia. FGF23 is also thought to be an inhibitor for PTH secretion. 12 Overexpression of FGF23 has been implicated in hereditary hypophosphatemic rickets. 12 In TIO, FGF23 is secreted in an unregulated fashion likely by tumor cells, causing marked hypophosphatemia and osteomalacia.
Patients with TIO and prolonged hypophosphatemia typically present with fatigue, bone pain, generalized weakness, and fractures secondary to abnormal bone matrix mineralization. TIO can present before a tumor is diagnosed, making it an important entity to understand and recognize, especially given the increasing amount of case reports of TIO in malignant neoplasms. Typically with TIO, serum phosphorus is low and serum 1,25(OH) 2 D levels are low or inappropriately normal. 25-hydroxyvitamin D (25(OH)D) and calcium levels are usually normal, though hypocalcemia has been described. ALP levels are often elevated and parathyroid hormone levels could be suppressed, mildly elevated, or even normal. A markedly elevated FGF23 level is usually the hallmark finding in TIO and provides strong support for a diagnosis of TIO. [11] [12] [13] Imaging to evaluate for occult tumor is indicated in patients with objective lab values suspicious of TIO. It is also equally important to discuss any family history of malignancies and to ensure that health care maintenance is up to date. A magnetic resonance imaging (MRI) or CT of the head and neck is usually advised given the fact that most TIO-related tumors are mesenchymal in origin. 12 If the tumor cannot be located, an octreotide scan can be performed, as many of these tumors express somatostatin receptors. If a tumor expressing octreotide receptors is located, short-term use of octreotide therapy can be used to rapidly correct the phosphorus preoperatively. 11, 13, 14 Primary treatment is resection of tumor and/or treatment of malignancy. If not resectable, vitamin D metabolites such as calcitriol and oral phosphate salts can be used in a similar fashion to the treatment of X-linked hypophosphatemia. 13 In our patient, both the hypophosphatemia and metastatic hepatic lesions were found at the same time. In addition, the patient was found to have no signs of osteomalacia on both physical examination and imaging. The lack of observed osteomalacia in this patient is likely due to the short duration of hypophosphatemia as the bone mineralization process was not yet impaired. She did however have the typical serological features of TIO such as a markedly elevated FGF23, an elevated ALP, a low-normal 1,25(OH) 2 D, a low PTH, and an elevated urinary fractional excretion of phosphorus. The patient did however exhibit some atypical features, including a slightly low 25(OH)D level and hypercalcemia. It is unlikely that the mildly low level of 25(OH)D is responsible for causing the severe hypophosphatemia found in this patient, but it certainly could have contributed. Although atypical, the hypercalcemia found in this patient could be a paraneoplastic manifestation of malignancy-associated interleukin (IL)-6 production, a product of bone metastases, or the result of a yet unknown process.
It is well known that malignant TIO confers increased morbidity because of the resulting bone pain, fractures, and weakness. It has also been suggested that the presence of TIO may be a marker of poor prognosis. 2, 6 It is important for future research to explore this relationship of TIO and increased mortality.
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